2Fenichel GM.Neurological complications of immunization.Ann Neurol,1982,12:119-128.
3Older SA,Battafarano DF,Enzenauer RJ,et al.Can immunization precipitate connectivetissue disease?Report of five cases of systemic lupus erythematosus and review of theliterature.Semin Arthritis Rheum,1999,29:131-139.
7Guiserix J.Systemic lupus erythematosus following hepatitis Bvaccine.Nephron,1996,74:441.
8Wharton CFP,Pietroni R.Polyarteritis after influenza vaccination.Br MedJ,1974,2:331-332.
9Maillefert JF,Sibilia J,Toussirot B,et al.Rheumatic disorders developed afterhepatitis B vaccination.Rheumatology,1999,38:978-983.
10Senecal JL,Bertrand C,Coutlee F.Severe exacerbation of systemic lupuserythematosus after hepatitis B vaccination and importance of pneumococcal vaccination inpatients with autosplenectomy:comment on the article by Battafarano et al.ArthritisRheum,1999,42:1307-1308.
3Needleman P, Isakson P C. The discovery and function of COX-2. J Rheumatol, 1997, 24 (Supp149):6-8.
4Amit S K, Alan B M, Brendan C C, et al. Ester and amide derivatives of the nonsteroidal anti-inflammatory drug,indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem, 2000, 43(15): 2860~2870.
5Hawkey C J. COX-2 inhibitor. Lancet, 1999, 353(9149):307-314.
6Willoughby D A,Moore A R,Colville P R.Cox-1,Cox-2 andCox-3and the future treatment of chronic inflammatory disease.Lancet,2000,355(9204):646-648.
7Vane J R, Booting R M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med, 1998, 104(3A):2S-8S.
8Christopher J. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: consensus and controversy. Am J Med, 2001, 110(IA): 1S-3S.
9Raymond V G. Merck announce voluntary worldwide withdrawal of VIOXX [DB/OL]. http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp, 2004-09-30.
10Pfizer statement on new information regarding cardiovascular safety of celebrex [DB/OL]. http://www.celebrex.com/cardiovascular_safety_ of_celebrex_tp.asp, 2004-12-17.